UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
For the quarterly period ended June 30, 2000
-----------------------
[] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________________ to _______________
Commission File No. 33-55254-09
---------------
Rocky Point Pharmaceuticals, Inc.
(Exact name of Small Business Issuer as specified in its charter)
NEVADA 87-0434293
-------------------------------- ---------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification Number)
incorporation or organization)
50 West Broadway, Suite 1111
Salt Lake City, Utah 84101
-------------------------------------------- ------------------
(Address of principal executive offices) (Zip Code)
Issuer's telephone number, including area code (801) 363-1600
------------------------------
Indicate by check mark whether the Issuer (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the Issuer
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [X] Yes [ ] No
Indicate the number of shares outstanding of each of the Issuer's
classes of common stock, as of the latest practicable date.
Class Outstanding as of June 30, 2000
------------------------------------ -------------------------------
$.001 PAR VALUE CLASS A COMMON STOCK 1,000,000 SHARES
<PAGE>
PART 1 - FINANCIAL INFORMATION
Item 1. Financial Statements.
BASIS OF REPRESENTATION
General
The accompanying unaudited financial statements have been prepared in
accordance with the instructions to Form 10-QSB and, therefore, do not include
all information and footnotes necessary for a complete presentation of financial
position, results of operations, cash flows and stockholders' equity in
conformity with generally accepted accounting principles. In the opinion of
management, all adjustments considered necessary for a fair presentation of the
results of operations and financial position have been included and all such
adjustments are of a normal recurring nature. Operating results for the quarter
ended June 30, 2000, are not necessarily indicative of the results that can be
expected for the year ending December 31, 2000.
Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations
The Company has had no operational history and has yet to engage in
business of any kind. All risks inherent in new and inexperienced enterprises
are inherent in the Company's business. The Company has not made a formal study
of the economic potential of any business. At the present, the Company has not
identified any assets or business opportunities for acquisition.
The Company has no liquidity and no presently available capital
resources, such as credit lines, guarantees, etc. and should a merger or
acquisition prove unsuccessful, it is possible that the Company may be dissolved
by the State of Nevada for failing to file reports. Should management decide not
to further pursue its acquisition activities, management may abandon its
activities and the shares of the Company would become worthless.
Based on current economic and regulatory conditions, Management
believes that it is possible, if not probable, for a company like the Company,
without assets or liabilities, to negotiate a merger or acquisition with a
viable private company. The opportunity arises principally because of the high
legal and accounting fees and the length of time associated with the
registration process of "going public". However, should any of these conditions
change, it is very possible that there would be little or no economic value for
anyone taking over control of the Company.
PART II - OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders
On May 31, 2000, a special shareholders' meeting was held.
Neil E. Crabtree and Dr. Robert Morrow were elected as directors. Mr.
Crabtree and Dr. Morrow each received unanimous votes as directors. 780,000
shares of the 1,000,000 shares outstanding were represented at the meeting.
Also, at the meeting the vote was unanimous to change the Company's
name from Wasatch Pharmaceutical, Inc. to Rocky Point Pharmaceuticals, Inc.
2
<PAGE>
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
99.1 Financial Statements as of June 30, 2000
27 Financial Data Schedule
(b) Reports on Form 8-K
On June 22, 2000, an 8-K was filed to announce a name change
and new officers and directors.
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of
1934, the Issuer has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Rocky Point Pharmaceuticals, Inc.
Dated: August 17, 2000 /s/ Neil E. Crabtree
--------------------------------------------
Neil E. Crabtree, President and Director
3
<PAGE>
Rocky Point Pharmaceuticals, Inc.
(A Development Stage Company)
BALANCE SHEETS
<TABLE>
<CAPTION>
June 30, December 31,
2000 1999
(Unaudited) (Audited)
---------------------- ----------------------
ASSETS
CURRENT ASSETS
<S> <C> <C>
Cash in bank $ 0 $ 0
---------------------- ---------------------
TOTAL CURRENT ASSETS 0 0
OTHER ASSETS
Organization costs 0 0
---------------------- ---------------------
0 0
---------------------- ---------------------
$ 0 $ 0
====================== =====================
LIABILITIES & EQUITY
CURRENT LIABILITIES
Accounts payable $ 0 $ 0
---------------------- ---------------------
TOTAL CURRENT LIABILITIES 0 0
STOCKHOLDERS' EQUITY
Common Stock $.001 par value:
Authorized - 100,000,000 shares
Issued and outstanding
1,000,000 shares 1,000 1,000
Additional paid-in capital 1,000 1,000
Deficit accumulated during the
development stage (2,000) (2,000)
---------------------- ---------------------
TOTAL STOCKHOLDERS' EQUITY 0 0
---------------------- ---------------------
$ 0 $ 0
====================== =====================
</TABLE>
F-1
<PAGE>
Rocky Point Pharmaceuticals, Inc.
(A Development Stage Company)
STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
4/14/86
Three Months Ended Six Months Ended (Date of
June 30, June 30, inception) to
2000 1999 2000 1999 6/30/00
---------------- --------------- --------------- --------------- ---------------
<S> <C> <C> <C> <C> <C>
Net sales $ 0 $ 0 $ 0 $ 0 $ 0
Cost of sales 0 0 0 0 0
---------------- --------------- --------------- --------------- ---------------
GROSS PROFIT 0 0 0 0 0
General and administrative expenses 0 0 0 0 0
---------------- --------------- --------------- --------------- ---------------
NET LOSS $ 0 $ 0 $ 0 $ 0 $ (2,000)
================ =============== =============== =============== ===============
Net income (loss) per weighted
average share $ .00 $ .00 $ .00 $ .00
================ =============== =============== ===============
Weighted average number of common
shares used to compute net income
(loss) per weighted average share 1,000,000 1,000,000 1,000,000 1,000,000
================ =============== =============== ===============
</TABLE>
F-2
<PAGE>
Rocky Point Pharmaceuticals, Inc.
(A Development Stage Company)
STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
4/14/86
(Date of
Six Months Ended June 30, Inception) to
2000 1999 6/30/00
--------------- --------------- ----------------
OPERATING ACTIVITIES
<S> <C> <C> <C>
Net (loss) $ 0 $ 0 $ (2,000)
Adjustments to reconcile net (loss) to cash used
by operating activities:
Amortization 0 0 50
--------------- --------------- ----------------
NET CASH USED
BY OPERATING ACTIVITIES 0 0 (1,950)
INVESTING ACTIVITIES
Organization costs 0 0 (50)
--------------- --------------- ----------------
NET CASH PROVIDED (USED)
BY INVESTING ACTIVITIES 0 0 (50)
FINANCING ACTIVITIES
Proceeds from sale of common stock 0 0 2,000
--------------- --------------- ----------------
NET CASH PROVIDED BY
FINANCING ACTIVITIES 0 0 2,000
--------------- --------------- ----------------
INCREASE IN CASH
AND CASH EQUIVALENTS 0 0 0
Cash and cash equivalents at beginning of year 0 0 0
--------------- --------------- ----------------
CASH AND CASH EQUIVALENTS
AT END OF PERIOD $ 0 $ 0 $ 0
=============== =============== ================
</TABLE>
F-3
